SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer
April 13, 2021 09:00 ET
|
SEngine Precision Medicine
SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS®...
SEngine Precision Medicine’s PARIS® Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR’s Molecular Cancer Therapeutics
April 05, 2021 09:00 ET
|
SEngine Precision Medicine
SEATTLE, April 05, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids,...
SEngine Precision Medicine to Present Data on Predictive Value of PARIS® Test in Ovarian Cancer Patients at 2021 AACR Annual Conference
March 10, 2021 16:59 ET
|
SEngine Precision Medicine
SEATTLE, March 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today...
SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium
December 09, 2020 09:00 ET
|
SEngine Precision Medicine
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today...
SEngine Precision Medicine to Present Data from Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium
November 24, 2020 08:00 ET
|
SEngine Precision Medicine
SEATTLE, Nov. 24, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived tumor...
SEngine Precision Medicine’s PARIS® Test Identifies Novel Drug Combinations for PARP Inhibitor Resistant Ovarian Cancer in Study Published in EBioMedicine
October 20, 2020 16:00 ET
|
SEngine Precision Medicine
SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on...
SEngine Precision Medicine to Present at Society of Functional Precision Medicine Virtual Seminar on October 14
October 13, 2020 16:00 ET
|
SEngine Precision Medicine
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on...
SEngine Precision Medicine’s PARIS® Test to Guide Personalized Treatment Demonstrates Clinical Utility in Metastatic Colorectal Cancer Study Published in AACR’s Clinical Cancer Research
July 21, 2020 09:00 ET
|
SEngine Precision Medicine
SEATTLE, July 21, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on...
SEngine Precision Medicine Presents Innovative Data on the CLIA Certified PARIS® Test for Oncology Drug Sensitivity and the Future of Functional Precision Medicine at AACR 2020
June 22, 2020 09:00 ET
|
SEngine Precision Medicine
SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on...
SEngine Precision Medicine Presented Data at ASCO 2020 on Clinical Validation of the CLIA Certified PARIS® Test, a Revolutionary Organoid Based Assay, to Personalize Cancer Treatments
May 29, 2020 09:00 ET
|
SEngine Precision Medicine
SEATTLE, May 29, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on...